Details of the Drug Reposition

General Information of This Drug (ID: DMZL3IV)

Drug Name
Alemtuzumab   DMZL3IV
Synonyms Campath (TN); MabCampath (TN); Campath-1H (TN)
Therapeutic Class
Anticancer Agents
Drug Type
Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
8 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Leukemia DISNAKFL N.A. Approved [1]
Myeloproliferative neoplasm DIS5KAPA 2A20 Approved [2]
Acute myelogenous leukaemia DISCSPTN 2A41 Approved [3]
Chronic lymphocytic leukaemia DISEXWC3 2A82.0 Approved [4]
Immunodeficiency DIS093I0 4A00-4A85 Approved [5]
Systemic lupus erythematosus DISI1SZ7 4A40.0 Approved [6]
Systemic sclerosis DISF44L6 4A42 Approved [7]
Multiple sclerosis DISB2WZI 8A40 Approved [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Indications(s)
1 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Non-hodgkin lymphoma DISS2Y8A 2B33.5 Discontinued in Phase 2 [8]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Neuroblastoma DISVZBI4 2D11.2 Investigative [9]
------------------------------------------------------------------------------------

References

1 T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment. Int J Mol Sci. 2023 Jul 28;24(15):12106.
2 Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay. Leuk Res. 2004 Dec;28(12):1255-62.
3 Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant. 2009 May;15(5):610-7.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6770).
5 Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology. CNS Drugs. 2021 Nov;35(11):1173-1188.
6 Therapeutic Interventions of Tissue Specific Autoimmune Onset in Systemic Lupus Erythematosus. Mini Rev Med Chem. 2017;17(15):1418-1424.
7 Regulation of Monocyte Adhesion and Type I Interferon Signaling by CD52 in Patients With Systemic Sclerosis. Arthritis Rheumatol. 2021 Sep;73(9):1720-1730.
8 Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
9 A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.